{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T18:38:30Z","timestamp":1774723110492,"version":"3.50.1"},"reference-count":10,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,4,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objective.<\/jats:title>\n                  <jats:p>To study the effectiveness of prochlorperazine in aborting severe, intractable migraines in children.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study Design.<\/jats:title>\n                  <jats:p>Patients for this study were drawn from the population seen and evaluated in the Headache Center at Cincinnati Children's Hospital Medical Center. All patients were diagnosed with migraine headache by both clinical and International Headache Society criteria. The effectiveness of intravenous prochlorperazine in 20 consecutive patients referred to the emergency department for severe, prolonged migraines was retrospectively reviewed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Patients evaluated in this study presented with a mean headache severity of 8.4 on a 0- to 10-point scale and an average duration of 54 hours. At 1 hour, 90% of the patients reported feeling better with 50% becoming pain-free. A 50% or greater reduction in severity occurred in 75% of patients at 1 hour and in 95% at 3 hours. At 3 hours, 95% of the patients reported feeling better, and 60% were pain-free. Only 1 patient failed to respond to prochlorperazine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Prochlorperzaine was shown to be highly effective in aborting intractable migraines in children. It was well tolerated with no significant side effects. Additional large, double-blinded, randomized, placebo-controlled studies are needed to further investigate its effectiveness.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.107.4.e62","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:55:51Z","timestamp":1092441351000},"page":"e62-e62","source":"Crossref","is-referenced-by-count":74,"title":["Tolerability and Effectiveness of Prochlorperazine for Intractable Migraine in Children"],"prefix":"10.1542","volume":"107","author":[{"given":"Marielle A.","family":"Kabbouche","sequence":"first","affiliation":[{"name":"From the Divisions of Neurology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Liisa Bentti","family":"Vockell","sequence":"additional","affiliation":[{"name":"From the Divisions of Neurology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan L.","family":"LeCates","sequence":"additional","affiliation":[{"name":"From the Divisions of Neurology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott W.","family":"Powers","sequence":"additional","affiliation":[{"name":"Psychology, Cincinnati Children's Hospital Medical Center; and the"},{"name":"University of Cincinnati College of Medicine, Cincinnati, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Hershey","sequence":"additional","affiliation":[{"name":"From the Divisions of Neurology and"},{"name":"University of Cincinnati College of Medicine, Cincinnati, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2001,4,1]]},"reference":[{"key":"2021121003403592200_B1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/bmj.309.6957.765","article-title":"Prevalence of headache and migraine in schoolchildren.","volume":"309","author":"Abu-Arefeh","year":"1994","journal-title":"Br Med J"},{"key":"2021121003403592200_B2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1046\/j.1526-4610.1999.3907494.x","article-title":"Epidemiology of migraine among students from randomly selected secondary schools in Lodz.","volume":"39","author":"Split","year":"1999","journal-title":"Headache"},{"key":"2021121003403592200_B3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1526-4610.1993.hed3301029.x","article-title":"Impact of migraine in the United States: data from the National Health Interview Survey.","volume":"33","author":"Stang","year":"1993","journal-title":"Headache"},{"key":"2021121003403592200_B4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1212\/WNL.48.1.103","article-title":"Ibuprofen or acetaminophen for the acute treatment of migraine in children.","volume":"48","author":"Ha\u0308ma\u0308la\u0308inen","year":"1997","journal-title":"Neurology"},{"key":"2021121003403592200_B5","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1001\/jama.1989.03420080094038","article-title":"Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache.","volume":"261","author":"Jones","year":"1989","journal-title":"JAMA"},{"key":"2021121003403592200_B6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1212\/WNL.49.3.650","article-title":"Dopamine and migraine.","volume":"49","author":"Peroutka","year":"1997","journal-title":"Neurology"},{"key":"2021121003403592200_B7","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0196-0644(54)00222-3","article-title":"Intravenous versus rectal prochlorperazine in the treatment of benign vascular or tension headache: a randomized, prospective, double-blind trial.","volume":"24","author":"Thomas","year":"1994","journal-title":"Ann Emerg Med"},{"key":"2021121003403592200_B8","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0735-6757(96)90171-0","article-title":"Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache.","volume":"14","author":"Jones","year":"1996","journal-title":"Am J Emerg Med"},{"key":"2021121003403592200_B9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1553-2712.1998.tb02463.x","article-title":"Intravenous ketorolac vs intravenous prochlorperaxine for the treatment of migraine headaches.","volume":"5","author":"Seim","year":"1998","journal-title":"Acad Emerg Med"},{"key":"2021121003403592200_B10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0022-3476(58)80166-3","article-title":"Treatment of nausea and vomiting in children with prochlorperazine.","volume":"53","author":"Daeschner","year":"1958","journal-title":"J Pediatr"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/107\/4\/e62\/841844\/e62.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/107\/4\/e62\/841844\/e62.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T10:44:00Z","timestamp":1639133040000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/107\/4\/e62\/63413\/Tolerability-and-Effectiveness-of-Prochlorperazine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4,1]]},"references-count":10,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2001,4,1]]},"published-print":{"date-parts":[[2001,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.107.4.e62","relation":{},"ISSN":["1098-4275","0031-4005"],"issn-type":[{"value":"1098-4275","type":"electronic"},{"value":"0031-4005","type":"print"}],"subject":[],"published":{"date-parts":[[2001,4,1]]}}}